22 June 2021Histogen (HSTO.Q) and Amerimmune Announce Positive Top-Line Study Results for…Kieran Robertson Histogen (HSTO.Q), and its partner Amerimmune, today announced top-line results from its Phase 1 study of emricasan in mild symptomatic COVID-19 patients to assess safety, tolerability, and preliminary efficacy….